Abstract

A REVIEW ARTICLE ON DAPRODUSTAT- AN ALTERNATIVE OPTION FOR ANEMIAASSOCIATED WITH CHRONIC RENAL FAILURE

*Dr. Rajithasree Tripuramallu, Mrs. Bongirwar Nidhi, Dr. Chandrasekhara Rao Baru, Nikitha Gunti and Deshamalla Samatha

.

Abstract

Anemia is defined as a decrease in the red blood cells which is one of the most common haematological disorder usually associated with chronic diseases. Anemia of renal disease is common due to decreased erythropoietin production which is known as anemia of chronic kidney disease (CKD). It is a form of normocytic, normochromic, hypoproliferative anemia, frequently associated with poor outcomes in chronic kidney disease and confers an increased mortality risk. It is commonly managed with oral or intravenous iron supplements and with erythropoiesis stimulating agents (ESA). Daprodustat is an oral hypoxia- inducible factor propyl hydroxylase inhibitor. In patients with chronic kidney disease who are not undergoing dialysis the efficacy and safety of daprodustat is compared with the conventional erythropoiesis - stimulating agent darbepoetin alfa in this review. Daprodustat increases endogenous erythropoietin in a dose dependent manner in 6-8 hours after administration. It is primarily metabolized by CYP2C8 (95% contribution) with a minor contribution by CYP3A4 (5%). It was absorbed across the gastrointestinal tract and 18% cleared by hepatic extraction. The outcomes were the mean change in the hemoglobin level from baseline and the major adverse event is cardiovascular event. It is being evaluated as an oral alternative to conventional erythropoiesis- stimulating therapy.

Keywords: Chronic Kidney Disease, Anemia, Renal failure, Erythropoiesis stimulating harmone, Hemoglobin, Daprodustat, Efficacy, Red blood cell, Prolyl hydroxylase inhibitors, Clinical trials, Darbepoietin, Dialysis, Erythropoietin.